The global regulatory landscape for cosmetics is undergoing rapid transformation. Alternatives for cosmetic animal testing are at the center of this shift.
Regulatory authorities increasingly expect modern science, in vitro data, and computational models, impacting development, safety, and market access strategies.
In this article, we highlight recent advancements related to alternatives for cosmetic animal testing, including new guidance from the Food and Drug Administration, regulatory initiatives in the European Union, and technical updates in China that reinforce stricter oversight of cosmetics.
FDA advances the use of alternatives to animal testing
The Food and Drug Administration (FDA) has issued a draft guidance encouraging the use of New Approach Methodologies (NAMs) as alternatives to animal testing in the safety assessment of regulated products.
These methodologies include human biology-based in vitro systems, such as organs-on-chips, and computational in silico models.
The document is part of a broader agency effort to move away from treating animal testing as the default method. It aligns with scientific advancements and recent legislative changes, such as the FDA Modernization Act 2.0.
The guidance establishes clear principles for regulatory acceptance of these approaches. It includes defining the context of use, ensuring human biological relevance, technical robustness, and fitness for regulatory purpose.
Although the primary focus is on the pharmaceutical sector, the initiative signals an important trend for the cosmetics industry as well. Particularly, regarding scientific evidence generation and the growing expectation of regulatory acceptance of alternative data.
China strengthens oversight with new official cosmetic testing methods
China has also taken important steps by updating its technical safety standards for cosmetics. The country has incorporated new official analytical methods, including specific tests for cannabidiol (CBD) and other substances of regulatory interest.
This measure strengthens the oversight capacity of the National Medical Products Administration. It standardizes laboratory testing used in registrations, notifications, and post-market activities.
With more sensitive, specific methods, expectations for analytical data quality are rising. This is especially true for imported products.
In practice, this requires stronger alignment between global testing strategies and the specific technical expectations of the Chinese market.
European Union expands the use of AI and data in regulatory assessment
In the European Union, regulators have updated a joint work plan to expand the use of artificial intelligence and big data in regulatory processes over the coming years.
The initiative, led by the European Medicines Agency, aims to improve data interoperability, support evidence generation, and streamline regulatory decision-making.
This movement reinforces the role of real-world data, advanced analytics, and digital tools in evaluating the safety and performance of regulated products.
Anvisa strengthens its international role in medical devices
In Brazil, the Anvisa has taken on new strategic responsibilities within the International Medical Device Regulators Forum (IMDRF). This took place during the 29th meeting of the forum’s Management Committee, held in Singapore.
The IMDRF is the leading global platform for regulatory cooperation in medical devices and IVDs. It focused on harmonizing requirements and strengthening regulatory best practices.
Among the highlights, Anvisa has assumed co-chairmanship of the Quality Management System (QMS) Working Group, alongside the European Commission. Also, the vice-chair role of the Medical Device Single Audit Program (MDSAP).
These positions reinforce Brazil’s role in international technical discussions on audits, quality systems, and regulatory harmonization.
For companies operating in both Brazilian and international markets, this development may influence—over time—how quality requirements, audits, and technical evidence are discussed and recognized across different authorities.
Updates that are becoming part of regulatory strategy
Initiatives from the FDA, the European Union, and China show that alternatives for cosmetic animal testing are no longer a future trend—they are now a strategic element of the present.
For companies operating across multiple markets, keeping up with these changes is essential to reduce regulatory risks, avoid rework in testing, and increase predictability in submission processes.
More than an ethical or technological matter, adopting alternative methods requires regulatory planning, assessment of acceptance by different authorities, and integration between development, testing, and market access strategies.
To stay up to date with these and other global regulatory developments, subscribe to the Sobel News Round Up and receive key insights impacting the cosmetics, medical device, and IVD sectors in every edition.
